Amneal Pharmaceuticals (AMRX) Competitors $10.09 +0.27 (+2.75%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$10.18 +0.09 (+0.88%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. ASND, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, and GRFSShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Amneal Pharmaceuticals (NASDAQ:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Which has more volatility and risk, AMRX or ASND? Amneal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Which has preferable earnings and valuation, AMRX or ASND? Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.79B1.13-$116.89M$0.011,009.00Ascendis Pharma A/S$393.54M30.74-$409.12M-$5.16-38.31 Does the media prefer AMRX or ASND? In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 10 mentions for Amneal Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.30 beat Amneal Pharmaceuticals' score of 1.17 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is AMRX or ASND more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals0.12% -189.49% 6.17% Ascendis Pharma A/S -54.94%N/A -24.31% Do institutionals & insiders believe in AMRX or ASND? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate AMRX or ASND? Amneal Pharmaceuticals currently has a consensus price target of $11.60, indicating a potential upside of 14.97%. Ascendis Pharma A/S has a consensus price target of $244.36, indicating a potential upside of 23.62%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAmneal Pharmaceuticals beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08B$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio1,010.0123.7675.1126.20Price / Sales1.13564.68470.8391.87Price / Cash7.07169.2537.0859.91Price / Book-28.835.3912.116.28Net Income-$116.89M$32.95M$3.29B$270.85M7 Day Performance4.89%2.61%1.58%3.58%1 Month Performance11.86%9.87%7.88%6.67%1 Year Performance19.13%1.49%61.66%27.73% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals2.6782 of 5 stars$10.09+2.7%$11.60+15.0%+20.7%$3.08B$2.79B1,010.018,100Positive NewsASNDAscendis Pharma A/S3.1501 of 5 stars$194.27+0.2%$243.36+25.3%+75.0%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.4707 of 5 stars$14.20-0.1%$16.95+19.4%-7.1%$11.86B$3.81B21.5127,811Positive NewsQGENQIAGEN4.4438 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$1.98B27.495,765Positive NewsBBIOBridgeBio Pharma4.3446 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$221.90M-12.66400Positive NewsMRNAModerna4.5286 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.24B-3.205,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1875 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.807 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.12B$4.44B21.379,000High Trading VolumeROIVRoivant Sciences2.8249 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoverageOptions VolumeRVMDRevolution Medicines4.2575 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst RevisionGap UpGRFSGrifols3.8709 of 5 stars$9.97+1.0%$10.30+3.3%+9.0%$6.85B$7.81B8.5223,822News CoveragePositive News Related Companies and Tools Related Companies ASND Competitors RDY Competitors QGEN Competitors BBIO Competitors MRNA Competitors VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRX Stock Alerts